Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 11

1.

Oral antiplatelet therapy and platelet inhibition: An experience from a tertiary care center.

Dalal JJ, Digrajkar A, Gandhi A.

Indian Heart J. 2016 Sep - Oct;68(5):624-631. doi: 10.1016/j.ihj.2015.12.022.

2.
3.

Adoption of prasugrel into routine practice: rationale and design of the Rijnmond Collective Cardiology Research (CCR) study in percutaneous coronary intervention for acute coronary syndromes.

Yetgin T, van der Linden MM, de Vries AG, Smits PC, Boersma E, van Geuns RJ, Zijlstra F; CCR Study Investigators..

Neth Heart J. 2014 Feb;22(2):55-61. doi: 10.1007/s12471-013-0472-1.

4.

Polymorphisms of MDR1, CYP2C19 and P2Y12 genes in Indian population: effects on clopidogrel response.

Shalia KK, Shah VK, Pawar P, Divekar SS, Payannavar S.

Indian Heart J. 2013 Mar-Apr;65(2):158-67. doi: 10.1016/j.ihj.2013.02.012.

5.

Platelet adenosine diphosphate receptor antagonists: ticlopidine to ticagrelor-a long continuing journey.

Kaul U, Mansoor AH.

Indian Heart J. 2012 Jan-Feb;64(1):54-9. doi: 10.1016/S0019-4832(12)60012-1. Review.

6.

Tocotrienols-induced inhibition of platelet thrombus formation and platelet aggregation in stenosed canine coronary arteries.

Qureshi AA, Karpen CW, Qureshi N, Papasian CJ, Morrison DC, Folts JD.

Lipids Health Dis. 2011 Apr 14;10:58. doi: 10.1186/1476-511X-10-58.

7.
8.
9.
10.
11.

Diabetes mellitus: a prothrombotic state implications for outcomes after coronary revascularization.

Cola C, Brugaletta S, Martín Yuste V, Campos B, Angiolillo DJ, Sabaté M.

Vasc Health Risk Manag. 2009;5(1):101-19. Review.

Items per page

Supplemental Content

Support Center